22.5 C
New York
Thursday, June 18, 2026

Tag: intellectual property

newssourceFORcompanyinformationcontent1marketreleases

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update.

Applied Therapeutics Reports Second Quarter 2025 Financial Results

- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD

Solventum Announces Launch of Secondary Offering of Common Stock

ST. PAUL, Minn., Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV, "Company" or "Solventum") today announced the launch of a secondary offering (the "Offering")...

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

Caris Life Sciences Reports Second Quarter 2025 Financial Results

IRVING, Texas, Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results...

G. WILLI-FOOD INTERNATIONAL ANNOUNCES DIVIDEND DISTRIBUTION OF NIS 20 MILLION (US$5.8 MILLION)

YAVNE, Israel, Aug. 12, 2025 /PRNewswire/ -- G. Willi-Food International Ltd. (NASDAQ: WILC) (TASE: WILF) (the "Company" or "Willi-Food"), a global company that specializes...

G. WILLI-FOOD INTERNATIONAL REPORTS THE RESULTS OF SECOND QUARTER 2025 WITH RECORD HIGH RESULTS

THE COMPANY REPORT ITS HIGHEST-EVER QUARTERLY REVENUE, OPERATING PROFIT, PROFIT BEFORE TAX, AND NET INCOME YAVNE, Israel, Aug. 12, 2025 /PRNewswire/ -- G. Willi-Food International...

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"...

Neo Performance Materials Reports Second Quarter 2025 Results

Neo Raises Full Year Guidance on Strong First Half-Year Performance TORONTO, Aug. 12, 2025 /CNW/ - Neo Performance Materials Inc. ("Neo") (TSX: NEO) (OTCQX: NOPMF) reported...

Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results

LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2025.

China Literature Announces 2025 Interim Results

HONG KONG, Aug. 12, 2025 /PRNewswire/ -- China Literature Limited ("China Literature" or "the Company", stock code: 0772), a leading online literature and intellectual...

Progress on share buyback programme

Progress on share buyback programme

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsIntellectual property

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers